The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...

Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for ...

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...

REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...

Leerink reiterated an Outperform rating and $24 price target on Regenxbio (RGNX) after Sarepta (SRPT) announced a Duchenne muscular dystrophy ...

We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

ROCKVILLE, Md., March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY ...